PT - JOURNAL ARTICLE AU - Costantini, Veronica P. AU - Nguyen, Kenny AU - Lyski, Zoe AU - Novosad, Shannon AU - Bardossy, Ana C. AU - Lyons, Amanda K. AU - Gable, Paige AU - Kutty, Preeta K. AU - Lutgring, Joseph D. AU - Brunton, Amanda AU - Thornburg, Natalie AU - Brown, Allison C. AU - McDonald, L. Clifford AU - Messer, William AU - Vinjé, Jan TI - Development and validation of an enzyme immunoassay for detection and quantification of SARS-CoV-2 salivary IgA and IgG AID - 10.1101/2021.09.03.21263078 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.03.21263078 4099 - http://medrxiv.org/content/early/2021/09/07/2021.09.03.21263078.short 4100 - http://medrxiv.org/content/early/2021/09/07/2021.09.03.21263078.full AB - Oral fluids offer a non-invasive sampling method for the detection of antibodies. Quantification of IgA and IgG antibodies in saliva allows studies of the mucosal and systemic immune response after natural infection or vaccination. We developed and validated an enzyme immunoassay (EIA) to detect and quantify salivary IgA and IgG antibodies against the prefusion-stabilized form of the SARS-CoV-2 spike protein. Normalization against total antibody isotype was performed to account for specimen differences, such as collection time and sample volume. Saliva samples collected from 187 SARS-CoV-2 confirmed cases enrolled in 2 cohorts and 373 pre-pandemic saliva samples were tested. The sensitivity of both EIAs was high (IgA: 95.5%; IgG: 89.7%) without compromising specificity (IgA: 99%; IgG: 97%). No cross reactivity with seasonal coronaviruses was observed. The limit of detection for SARS-CoV-2 salivary IgA and IgG assays were 1.98 ng/mL and 0.30 ng/mL, respectively. Salivary IgA and IgG antibodies were detected earlier in patients with mild COVID-19 symptoms than in severe cases. However, severe cases showed higher salivary antibody titers than those with a mild infection. Salivary IgA titers quickly decreased after 6 weeks in mild cases but remained detectable until at least week 10 in severe cases. Salivary IgG titers remained high for all patients, regardless of disease severity. In conclusion, EIAs for both IgA and IgG had high specificity and sensitivity for the confirmation of current or recent SARS-CoV-2 infections and evaluation of the IgA and IgG immune response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported in part by federal funds from the National Institute of Allergy and Infectious Diseases NIAID R01AI145835 (W. M). Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the US Centers for Disease Control and Prevention.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy (See, e.g., 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. 241(d); 5 U.S.C. 552a; 44 U.S.C. 3501 et seq.). The study was approved by the Institutional Review Boards of the Oregon Health & Science University (IRB 21230) (cohort II).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDatasets generated and analyzed during the current study are available from the corresponding author on reasonable request.